Pfizer considering OTC version of Viagra

Share this article:
Pfizer said in a published report Wednesday it is considering an OTC version of its erectile dysfunction (ED) drug Viagra to stave off tough competition from Lilly’s longer lasting Cialis. “As with many of our products, Pfizer has routinely evaluated a number of options (for Viagra), including different formulations, new indications, over-the-counter, etc. and continues to do so,” Pfizer said in a statement provided to Reuters. It was the first time Pfizer has disclosed interest in an OTC form of Viagra, a company spokeswoman told Reuters. The spokeswoman declined further comment when asked about the possible merits of a non-prescription form of the drug. Pfizer disclosed the OTC option in response to an article in the Jan. 11 edition of the British business magazine The Business that said Pfizer had described such discussions. The magazine article also said Pfizer was planning an oral-spray version of Viagra being developed by Novadel, a US drug delivery firm. “We are not pursuing a spray version of Viagra,” Pfizer told Reuters. Novadel CFO Michael Spicer called the report of its involvement with Pfizer unfounded. Viagra held a 56.6% lead of the US ED drug market, with $615 million in sales for the first nine months of 2006, according to IMS Health. However, Viagra’s sales were down 6%. Cialis captured 27% of the US ED market, with sales up 26% to $294 million, while GlaxoSmithKline and Schering-Plough’s Levitra claimed 13.3%, with sales up 30% to $144 million.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...